Cue Health shares are trading lower after Goldman Sachs downgraded the stock from Buy to Neutral and lowered its price target from $2.75 to $0.75.
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs downgraded Cue Health's stock from Buy to Neutral and lowered its price target from $2.75 to $0.75, causing the shares to trade lower.
June 02, 2023 | 3:30 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Cue Health's stock downgraded by Goldman Sachs from Buy to Neutral, with a reduced price target from $2.75 to $0.75, leading to lower trading.
Goldman Sachs' downgrade and reduced price target for Cue Health's stock directly impacts the stock's short-term performance. The downgrade from Buy to Neutral indicates a less favorable outlook, while the lowered price target from $2.75 to $0.75 suggests a significant decrease in the stock's perceived value. This news is likely to cause a negative sentiment among investors, leading to a decline in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100